Investors Expect Biopharma Run-Up To Cool In Summer, Heat Up In Fall
Executive Summary
Biotech and pharma stocks have continued their hot streak unabated this year, but if the summer brings little news and a broader market pull-back the sector is likely to cool. Wall Street is hopeful that any chill will be gone by the fall, with more clinical and regulatory milestones.